APO Research
Talk to an analyst

APO RESEARCH · REPORT

Vigabatrin

Compare research editions
View pricing & licenses

Selected research

Market Structure

Global Vigabatrin Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032

20 December 2025194 pages

Choose your research edition.

Industry ResearchVigabatrin Industry Research Report 2026123 pages · $2,950 USDIndustry Growth & TrendsGlobal Vigabatrin Industry Growth and Trends Forecast to 2032101 pages · $3,450 USDMarket StructureGlobal Vigabatrin Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032194 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Vigabatrin Market Outlook and Growth Opportunities 2026198 pages · $4,250 USDMarket Analysis & ForecastGlobal Vigabatrin Market Analysis and Forecast 2026-2032198 pages · $4,950 USD

Market perspective

The global Vigabatrin market is projected to grow from US$ million in 2026 to US$ million by 2032, implying a CAGR of % over 2026-2032.

The US & Canada market for Vigabatrin is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

The Europe market for Vigabatrin is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Read the full market overview

The Asia Pacific market for Vigabatrin is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

The China market for Vigabatrin is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Leading global manufacturers of Vigabatrin include Sanofi, Novartis, Upsher-Smith, Perrigo, Lundbeck, Grindeks, Endo International, Dr. Fisher Farma and Cipla, among others. In 2025, the top three vendors together accounted for approximately % of global revenue.

This report provides an overview of the global Vigabatrin market in terms of sales, revenue, and price, analyzing global market trends using historical revenue and sales data for 2021-2025, estimates for 2026, and projected CAGRs through 2032.

The study covers key producers of Vigabatrin and sales in major regions and countries, assesses future market potential, and highlights priority regions and countries for segmenting the market into sub-sectors, with country-specific market value data for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, the Middle East, Africa, and other countries.

The report also presents Vigabatrin sales, revenue, market share, and industry ranking for the main manufacturers for 2021-2026, identifies the major stakeholders in the global market, and analyzes their competitive landscape and market positioning based on recent developments and segmental revenues.

In addition, the report analyzes segment data by Type and Application—covering sales, revenue, and price—for 2021-2032, and evaluates and forecasts the Vigabatrin market size, projected growth trends, production technologies, key applications, and end-use industries.

Vigabatrin Segment by Company

Sanofi

Novartis

Upsher-Smith

Perrigo

Lundbeck

Grindeks

Endo International

Dr. Fisher Farma

Cipla

Benta Pharma Industries

Amneal Pharma

Vigabatrin Segment by Type

Tablet

Powder

Vigabatrin Segment by Application

Partial-Onset Seizures

Refractory Complex Partial Seizures

Infantile Spasms (IS)

Vigabatrin Segment by Region

North America

United States

Canada

Europe

Germany

France

U.K.

Italy

Netherlands

Asia-Pacific

China

Japan

South Korea

India

Australia

China Taiwan

Southeast Asia

South America

Mexico

Brazil

Argentina

Middle East & Africa

Turkey

Saudi Arabia

UAE

Study Objectives

1. To analyze and research the global status and future forecast, involving, production, value, consumption, growth rate (CAGR), market share, historical and forecast.

2. To present the key manufacturers, capacity, production, revenue, market share, and Recent Developments.

3. To split the breakdown data by regions, type, manufacturers, and Application.

4. To analyze the global and key regions market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify significant trends, drivers, influence factors in global and regions.

6. To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Vigabatrin market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Vigabatrin and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Vigabatrin.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Provides an overview of the Vigabatrin market, including product definition, global market growth prospects, market size, sales, and average price forecasts (2021-2032).

Chapter 2: Provides the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.

Chapter 3: Detailed analysis of Vigabatrin manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, etc.

Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 6: Sales of Vigabatrin in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space of each country in the world.

Chapter 7: Revenue of Vigabatrin in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space of each country in the world.

Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.

Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.

Chapter 10: Concluding Insights of the report

More report detail

Tables and figures
List of Tables Table 1. Vigabatrin Industry Trends Table 2. Vigabatrin Industry Drivers Table 3. Vigabatrin Industry Opportunities and Challenges Table 4. Vigabatrin Industry Restraints Table 5. Global Vigabatrin Revenue by Manufacturers (US$ Million) & (2021-2026) Table 6. Global Vigabatrin Revenue Market Share by Manufacturers (2021-2026) Table 7. Global Vigabatrin Sales by Manufacturers (K Units) & (2021-2026) Table 8. Global Vigabatrin Sales Market Share by Manufacturers Table 9. Global Vigabatrin Average Sales Price (US$/Unit) of Manufacturers (2021-2026) Table 10. Global Vigabatrin Industry Manufacturers Ranking, 2024 VS 2025 VS 2026 Table 11. Global Vigabatrin Key Manufacturers Manufacturing Sites & Headquarters Table 12. Global Vigabatrin Manufacturers, Product Type & Application Table 13. Global Vigabatrin Manufacturers Establishment Date Table 14. Global Manufacturers Market Concentration Ratio (CR5 and HHI) Table 15. Global Vigabatrin by Manufacturers Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue of 2025) Table 16. Major Manufacturers of Tablet Table 17. Major Manufacturers of Powder Table 18. Global Vigabatrin Sales by Type 2021 VS 2025 VS 2032 (K Units) Table 19. Global Vigabatrin Sales by Type (2021-2026) & (K Units) Table 20. Global Vigabatrin Sales by Type (2027-2032) & (K Units) Table 21. Global Vigabatrin Sales Market Share by Type (2021-2026) Table 22. Global Vigabatrin Sales Market Share by Type (2027-2032) Table 23. Global Vigabatrin Revenue by Type 2021 VS 2025 VS 2032 (K Units) Table 24. Global Vigabatrin Revenue by Type (2021-2026) & (K Units) Table 25. Global Vigabatrin Revenue by Type (2027-2032) & (K Units) Table 26. Global Vigabatrin Revenue Market Share by Type (2021-2026) Table 27. Global Vigabatrin Revenue Market Share by Type (2027-2032) Table 28. Major Manufacturers of Partial-Onset Seizures Table 29. Major Manufacturers of Refractory Complex Partial Seizures Table 30. Major Manufacturers of Infantile Spasms (IS) Table 31. Global Vigabatrin Sales by Application 2021 VS 2025 VS 2032 (K Units) Table 32. Global Vigabatrin Sales by Application (2021-2026) & (K Units) Table 33. Global Vigabatrin Sales by Application (2027-2032) & (K Units) Table 34. Global Vigabatrin Sales Market Share by Application (2021-2026) Table 35. Global Vigabatrin Sales Market Share by Application (2027-2032) Table 36. Global Vigabatrin Revenue by Application 2021 VS 2025 VS 2032 (K Units) Table 37. Global Vigabatrin Revenue by Application (2021-2026) & (K Units) Table 38. Global Vigabatrin Revenue by Application (2027-2032) & (K Units) Table 39. Global Vigabatrin Revenue Market Share by Application (2021-2026) Table 40. Global Vigabatrin Revenue Market Share by Application (2027-2032) Table 41. Global Vigabatrin Sales by Region: 2021 VS 2025 VS 2032 (K Units) Table 42. Global Vigabatrin Sales by Region (2021-2026) & (K Units) Table 43. Global Vigabatrin Sales Market Share by Region (2021-2026) Table 44. Global Vigabatrin Sales Forecasted by Region (2027-2032) & (K Units) Table 45. Global Vigabatrin Sales Forecasted Market Share by Region (2027-2032) Table 46. North America Vigabatrin Sales Growth Rate by Country: 2021 VS 2025 VS 2032 (K Units) Table 47. North America Vigabatrin Sales by Country (2021-2026) & (K Units) Table 48. North America Vigabatrin Sales by Country (2027-2032) & (K Units) Table 49. Europe Vigabatrin Sales Growth Rate by Country: 2021 VS 2025 VS 2032 (K Units) Table 50. Europe Vigabatrin Sales by Country (2021-2026) & (K Units) Table 51. Europe Vigabatrin Sales by Country (2027-2032) & (K Units) Table 52. Asia Pacific Vigabatrin Sales Growth Rate by Country: 2021 VS 2025 VS 2032 (K Units) Table 53. Asia Pacific Vigabatrin Sales by Country (2021-2026) & (K Units) Table 54. Asia Pacific Vigabatrin Sales by Country (2027-2032) & (K Units) Table 55. South America, Middle East and Africa Vigabatrin Sales Growth Rate by Country: 2021 VS 2025 VS 2032 (K Units) Table 56. South America, Middle East and Africa Vigabatrin Sales by Country (2021-2026) & (K Units) Table 57. South America, Middle East and Africa Vigabatrin Sales by Country (2027-2032) & (K Units) Table 58. Global Vigabatrin Revenue Grow Rate (CAGR) by Region: 2021 VS 2025 VS 2032 (US$ Million) Table 59. Global Vigabatrin Revenue by Region (2021-2026) & (US$ Million) Table 60. Global Vigabatrin Revenue by Region (2027-2032) & (US$ Million) Table 61. Global Vigabatrin Revenue Market Share by Region (2021-2026) Table 62. Global Vigabatrin Revenue Market Share by Region (2027-2032) Table 63. Sanofi Company Information Table 64. Sanofi Business Overview Table 65. Sanofi Vigabatrin Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 66. Sanofi Vigabatrin Product Portfolio Table 67. Sanofi Recent Development Table 68. Novartis Company Information Table 69. Novartis Business Overview Table 70. Novartis Vigabatrin Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 71. Novartis Vigabatrin Product Portfolio Table 72. Novartis Recent Development Table 73. Upsher-Smith Company Information Table 74. Upsher-Smith Business Overview Table 75. Upsher-Smith Vigabatrin Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 76. Upsher-Smith Vigabatrin Product Portfolio Table 77. Upsher-Smith Recent Development Table 78. Perrigo Company Information Table 79. Perrigo Business Overview Table 80. Perrigo Vigabatrin Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 81. Perrigo Vigabatrin Product Portfolio Table 82. Perrigo Recent Development Table 83. Lundbeck Company Information Table 84. Lundbeck Business Overview Table 85. Lundbeck Vigabatrin Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 86. Lundbeck Vigabatrin Product Portfolio Table 87. Lundbeck Recent Development Table 88. Grindeks Company Information Table 89. Grindeks Business Overview Table 90. Grindeks Vigabatrin Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 91. Grindeks Vigabatrin Product Portfolio Table 92. Grindeks Recent Development Table 93. Endo International Company Information Table 94. Endo International Business Overview Table 95. Endo International Vigabatrin Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 96. Endo International Vigabatrin Product Portfolio Table 97. Endo International Recent Development Table 98. Dr. Fisher Farma Company Information Table 99. Dr. Fisher Farma Business Overview Table 100. Dr. Fisher Farma Vigabatrin Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 101. Dr. Fisher Farma Vigabatrin Product Portfolio Table 102. Dr. Fisher Farma Recent Development Table 103. Cipla Company Information Table 104. Cipla Business Overview Table 105. Cipla Vigabatrin Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 106. Cipla Vigabatrin Product Portfolio Table 107. Cipla Recent Development Table 108. Benta Pharma Industries Company Information Table 109. Benta Pharma Industries Business Overview Table 110. Benta Pharma Industries Vigabatrin Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 111. Benta Pharma Industries Vigabatrin Product Portfolio Table 112. Benta Pharma Industries Recent Development Table 113. Amneal Pharma Company Information Table 114. Amneal Pharma Business Overview Table 115. Amneal Pharma Vigabatrin Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 116. Amneal Pharma Vigabatrin Product Portfolio Table 117. Amneal Pharma Recent Development Table 118. Key Raw Materials Table 119. Raw Materials Key Suppliers Table 120. Vigabatrin Distributors List Table 121. Vigabatrin Customers List Table 122. Research Programs/Design for This Report Table 123. Authors List of This Report Table 124. Secondary Sources Table 125. Primary Sources List of Figures Figure 1. Vigabatrin Product Image Figure 2. Global Vigabatrin Market Size (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global Vigabatrin Market Size (2021-2032) & (US$ Million) Figure 4. Global Vigabatrin Sales (2021-2032) & (K Units) Figure 5. Global Vigabatrin Average Price (US$/Unit) & (2021-2032) Figure 6. Global Top 5 and 10 Vigabatrin Players Market Share by Revenue in 2025 Figure 7. Manufacturers Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 8. Tablet Image Figure 9. Powder Image Figure 10. Global Vigabatrin Sales by Type (2021 VS 2025 VS 2032) & (K Units) Figure 11. Global Vigabatrin Sales Market Share 2021 VS 2025 VS 2032 Figure 12. Global Vigabatrin Sales Market Share by Type (2021-2032) Figure 13. Global Vigabatrin Revenue by Type (2021 VS 2025 VS 2032) & (K Units) Figure 14. Global Vigabatrin Revenue Market Share 2021 VS 2025 VS 2032 Figure 15. Global Vigabatrin Revenue Market Share by Type (2021-2032) Figure 16. Partial-Onset Seizures Image Figure 17. Refractory Complex Partial Seizures Image Figure 18. Infantile Spasms (IS) Image Figure 19. Global Vigabatrin Sales by Application (2021 VS 2025 VS 2032) & (K Units) Figure 20. Global Vigabatrin Sales Market Share 2021 VS 2025 VS 2032 Figure 21. Global Vigabatrin Sales Market Share by Application (2021-2032) Figure 22. Global Vigabatrin Revenue by Application (2021 VS 2025 VS 2032) & (K Units) Figure 23. Global Vigabatrin Revenue Market Share 2021 VS 2025 VS 2032 Figure 24. Global Vigabatrin Revenue Market Share by Application (2021-2032) Figure 25. North America Vigabatrin Sales and Growth Rate (2021-2032) & (K Units) Figure 26. North America Vigabatrin Sales Market Share by Country (2021-2032) Figure 27. U.S. Vigabatrin Sales and Growth Rate (2021-2032) & (K Units) Figure 28. Canada Vigabatrin Sales and Growth Rate (2021-2032) & (K Units) Figure 29. Mexico Vigabatrin Sales and Growth Rate (2021-2032) & (K Units) Figure 30. Europe Vigabatrin Sales and Growth Rate (2021-2032) & (K Units) Figure 31. Europe Vigabatrin Sales Market Share by Country (2021-2032) Figure 32. Germany Vigabatrin Sales and Growth Rate (2021-2032) & (K Units) Figure 33. France Vigabatrin Sales and Growth Rate (2021-2032) & (K Units) Figure 34. U.K. Vigabatrin Sales and Growth Rate (2021-2032) & (K Units) Figure 35. Italy Vigabatrin Sales and Growth Rate (2021-2032) & (K Units) Figure 36. Netherlands Vigabatrin Sales and Growth Rate (2021-2032) & (K Units) Figure 37. Asia Pacific Vigabatrin Sales and Growth Rate (2021-2032) & (K Units) Figure 38. Asia Pacific Vigabatrin Sales Market Share by Country (2021-2032) Figure 39. China Vigabatrin Sales and Growth Rate (2021-2032) & (K Units) Figure 40. Japan Vigabatrin Sales and Growth Rate (2021-2032) & (K Units) Figure 41. South Korea Vigabatrin Sales and Growth Rate (2021-2032) & (K Units) Figure 42. Southeast Asia Vigabatrin Sales and Growth Rate (2021-2032) & (K Units) Figure 43. India Vigabatrin Sales and Growth Rate (2021-2032) & (K Units) Figure 44. Australia Vigabatrin Sales and Growth Rate (2021-2032) & (K Units) Figure 45. South America, Middle East and Africa Vigabatrin Sales and Growth Rate (2021-2032) & (K Units) Figure 46. South America, Middle East and Africa Vigabatrin Sales Market Share by Country (2021-2032) Figure 47. Brazil Vigabatrin Sales and Growth Rate (2021-2032) & (K Units) Figure 48. South Africa Vigabatrin Sales and Growth Rate (2021-2032) & (K Units) Figure 49. Saudi Arabia Vigabatrin Sales and Growth Rate (2021-2032) & (K Units) Figure 50. Turkey Vigabatrin Sales and Growth Rate (2021-2032) & (K Units) Figure 51. Argentina Vigabatrin Sales and Growth Rate (2021-2032) & (K Units) Figure 52. UAE Vigabatrin Sales and Growth Rate (2021-2032) & (K Units) Figure 53. Egypt Vigabatrin Sales and Growth Rate (2021-2032) & (K Units) Figure 54. Chile Vigabatrin Sales and Growth Rate (2021-2032) & (K Units) Figure 55. Global Vigabatrin Revenue (CAGR) by Region: 2021 VS 2025 VS 2032 (US$ Million) Figure 56. Global Vigabatrin Revenue Market Share by Region in Percentage: 2025 Versus 2032 Figure 57. North America Vigabatrin Revenue (2021-2032) & (US$ Million) Figure 58. North America Vigabatrin Revenue Share by Country: 2021 VS 2025 VS 2032 Figure 59. Europe Vigabatrin Revenue (2021-2032) & (US$ Million) Figure 60. Europe Vigabatrin Revenue Share by Country: 2021 VS 2025 VS 2032 Figure 61. Asia-Pacific Vigabatrin Revenue (2021-2032) & (US$ Million) Figure 62. Asia-Pacific Vigabatrin Revenue Share by Country: 2021 VS 2025 VS 2032 Figure 63. South America, Middle East and Africa Vigabatrin Revenue (2021-2032) & (US$ Million) Figure 64. South America, Middle East and Africa Vigabatrin Revenue Share by Country: 2021 VS 2025 VS 2032 Figure 65. Vigabatrin Value Chain Figure 66. Manufacturing Cost Structure Figure 67. Vigabatrin Production Mode & Process Figure 68. Direct Comparison with Distribution Share Figure 69. Distributors Profiles Figure 70. Years Considered Figure 71. Research Process Figure 72. Key Executives Interviewed

Scope & coverage.

Types
  • Tablet
  • Powder
Applications
  • Partial-Onset Seizures
  • Refractory Complex Partial Seizures
  • Infantile Spasms (IS)
Companies covered
  • Sanofi
  • Novartis
  • Upsher-Smith
  • Perrigo
  • Lundbeck
  • Grindeks
  • Endo International
  • Dr. Fisher Farma
  • Cipla
  • Benta Pharma Industries
  • Amneal Pharma

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Global Vigabatrin Market Size, 2021 VS 2025 VS 2032
  3. 1.3 Global Vigabatrin Market Size Estimates and Forecasts (2021-2032)
  4. 1.4 Global Vigabatrin Sales Estimates and Forecasts (2021-2032)
  5. 1.5 Global Vigabatrin Market Average Price (2021-2032)
  6. 1.6 Assumptions and Limitations
  7. 1.7 Study Goals and Objectives
2 Global Vigabatrin Market Dynamics
  1. 2.1 Vigabatrin Industry Trends
  2. 2.2 Vigabatrin Industry Drivers
  3. 2.3 Vigabatrin Industry Opportunities and Challenges
  4. 2.4 Vigabatrin Industry Restraints
3 Vigabatrin Market by Manufacturers
  1. 3.1 Global Vigabatrin Revenue by Manufacturers (2021-2026)
  2. 3.2 Global Vigabatrin Sales by Manufacturers (2021-2026)
  3. 3.3 Global Vigabatrin Average Sales Price by Manufacturers (2021-2026)
  4. 3.4 Global Vigabatrin Industry Manufacturers Ranking, 2024 VS 2025 VS 2026
  5. 3.5 Global Vigabatrin Key Manufacturers Manufacturing Sites & Headquarters
  6. 3.6 Global Vigabatrin Manufacturers, Product Type & Application
  7. 3.7 Global Vigabatrin Manufacturers Establishment Date
  8. 3.8 Market Competitive Analysis
  9. 3.8.1 Global Vigabatrin Market CR5 and HHI
  10. 3.8.2 Global Top 5 and 10 Vigabatrin Players Market Share by Revenue in 2025
  11. 3.8.3 2025 Vigabatrin Tier 1, Tier 2, and Tier 3
4 Vigabatrin Market by Type
  1. 4.1 Vigabatrin Type Introduction
  2. 4.1.1 Tablet
  3. 4.1.2 Powder
  4. 4.2 Global Vigabatrin Sales by Type
  5. 4.2.1 Global Vigabatrin Sales by Type (2021 VS 2025 VS 2032)
  6. 4.2.2 Global Vigabatrin Sales by Type (2021-2032)
  7. 4.2.3 Global Vigabatrin Sales Market Share by Type (2021-2032)
  8. 4.3 Global Vigabatrin Revenue by Type
  9. 4.3.1 Global Vigabatrin Revenue by Type (2021 VS 2025 VS 2032)
  10. 4.3.2 Global Vigabatrin Revenue by Type (2021-2032)
  11. 4.3.3 Global Vigabatrin Revenue Market Share by Type (2021-2032)
5 Vigabatrin Market by Application
  1. 5.1 Vigabatrin Application Introduction
  2. 5.1.1 Partial-Onset Seizures
  3. 5.1.2 Refractory Complex Partial Seizures
  4. 5.1.3 Infantile Spasms (IS)
  5. 5.2 Global Vigabatrin Sales by Application
  6. 5.2.1 Global Vigabatrin Sales by Application (2021 VS 2025 VS 2032)
  7. 5.2.2 Global Vigabatrin Sales by Application (2021-2032)
  8. 5.2.3 Global Vigabatrin Sales Market Share by Application (2021-2032)
  9. 5.3 Global Vigabatrin Revenue by Application
  10. 5.3.1 Global Vigabatrin Revenue by Application (2021 VS 2025 VS 2032)
  11. 5.3.2 Global Vigabatrin Revenue by Application (2021-2032)
  12. 5.3.3 Global Vigabatrin Revenue Market Share by Application (2021-2032)
6 Global Vigabatrin Sales by Region
  1. 6.1 Global Vigabatrin Sales by Region: 2021 VS 2025 VS 2032
  2. 6.2 Global Vigabatrin Sales by Region (2021-2032)
  3. 6.2.1 Global Vigabatrin Sales by Region (2021-2026)
  4. 6.2.2 Global Vigabatrin Sales Forecasted by Region (2027-2032)
  5. 6.3 North America
  6. 6.3.1 North America Vigabatrin Sales Growth Rate by Country: 2021 VS 2025 VS 2032
  7. 6.3.2 North America Vigabatrin Sales by Country (2021-2032)
  8. 6.3.3 U.S.
  9. 6.3.4 Canada
  10. 6.3.5 Mexico
  11. 6.4 Europe
  12. 6.4.1 Europe Vigabatrin Sales Growth Rate by Country: 2021 VS 2025 VS 2032
  13. 6.4.2 Europe Vigabatrin Sales by Country (2021-2032)
  14. 6.4.3 Germany
  15. 6.4.4 France
  16. 6.4.5 U.K.
  17. 6.4.6 Italy
  18. 6.4.7 Netherlands
  19. 6.5 Asia Pacific
  20. 6.5.1 Asia Pacific Vigabatrin Sales Growth Rate by Country: 2021 VS 2025 VS 2032
  21. 6.5.2 Asia Pacific Vigabatrin Sales by Country (2021-2032)
  22. 6.5.3 China
  23. 6.5.4 Japan
  24. 6.5.5 South Korea
  25. 6.5.6 Southeast Asia
  26. 6.5.7 India
  27. 6.5.8 Australia
  28. 6.6 South America, Middle East and Africa
  29. 6.6.1 South America, Middle East and Africa Vigabatrin Sales Growth Rate by Country: 2021 VS 2025 VS 2032
  30. 6.6.2 South America, Middle East and Africa Vigabatrin Sales by Country (2021-2032)
  31. 6.6.3 Brazil
  32. 6.6.4 South Africa
  33. 6.6.5 Saudi Arabia
  34. 6.6.6 Turkey
  35. 6.6.6 Argentina
  36. 6.6.6 UAE
  37. 6.6.6 Egypt
  38. 6.6.6 Chile
7 Global Vigabatrin Revenue by Region
  1. 7.1 Global Vigabatrin Revenue by Region
  2. 7.1.1 Global Vigabatrin Revenue by Region: 2021 VS 2025 VS 2032
  3. 7.1.2 Global Vigabatrin Revenue by Region (2021-2026)
  4. 7.1.3 Global Vigabatrin Revenue by Region (2027-2032)
  5. 7.1.4 Global Vigabatrin Revenue Market Share by Region (2021-2032)
  6. 7.2 North America
  7. 7.2.1 North America Vigabatrin Revenue (2021-2032)
  8. 7.2.2 North America Vigabatrin Revenue Share by Country: 2021 VS 2025 VS 2032
  9. 7.3 Europe
  10. 7.3.1 Europe Vigabatrin Revenue (2021-2032)
  11. 7.3.2 Europe Vigabatrin Revenue Share by Country: 2021 VS 2025 VS 2032
  12. 7.4 Asia-Pacific
  13. 7.4.1 Asia-Pacific Vigabatrin Revenue (2021-2032)
  14. 7.4.2 Asia-Pacific Vigabatrin Revenue Share by Country: 2021 VS 2025 VS 2032
  15. 7.5 South America, Middle East and Africa
  16. 7.5.1 South America, Middle East and Africa Vigabatrin Revenue (2021-2032)
  17. 7.5.2 South America, Middle East and Africa Vigabatrin Revenue Share by Country: 2021 VS 2025 VS 2032
8 Company Profiles
  1. 8.1 Sanofi
  2. 8.1.1 Sanofi Company Information
  3. 8.1.2 Sanofi Business Overview
  4. 8.1.3 Sanofi Vigabatrin Sales, Price, Revenue and Gross Margin (2021-2026)
  5. 8.1.4 Sanofi Vigabatrin Product Portfolio
  6. 8.1.5 Sanofi Recent Developments
  7. 8.2 Novartis
  8. 8.2.1 Novartis Company Information
  9. 8.2.2 Novartis Business Overview
  10. 8.2.3 Novartis Vigabatrin Sales, Price, Revenue and Gross Margin (2021-2026)
  11. 8.2.4 Novartis Vigabatrin Product Portfolio
  12. 8.2.5 Novartis Recent Developments
  13. 8.3 Upsher-Smith
  14. 8.3.1 Upsher-Smith Company Information
  15. 8.3.2 Upsher-Smith Business Overview
  16. 8.3.3 Upsher-Smith Vigabatrin Sales, Price, Revenue and Gross Margin (2021-2026)
  17. 8.3.4 Upsher-Smith Vigabatrin Product Portfolio
  18. 8.3.5 Upsher-Smith Recent Developments
  19. 8.4 Perrigo
  20. 8.4.1 Perrigo Company Information
  21. 8.4.2 Perrigo Business Overview
  22. 8.4.3 Perrigo Vigabatrin Sales, Price, Revenue and Gross Margin (2021-2026)
  23. 8.4.4 Perrigo Vigabatrin Product Portfolio
  24. 8.4.5 Perrigo Recent Developments
  25. 8.5 Lundbeck
  26. 8.5.1 Lundbeck Company Information
  27. 8.5.2 Lundbeck Business Overview
  28. 8.5.3 Lundbeck Vigabatrin Sales, Price, Revenue and Gross Margin (2021-2026)
  29. 8.5.4 Lundbeck Vigabatrin Product Portfolio
  30. 8.5.5 Lundbeck Recent Developments
  31. 8.6 Grindeks
  32. 8.6.1 Grindeks Company Information
  33. 8.6.2 Grindeks Business Overview
  34. 8.6.3 Grindeks Vigabatrin Sales, Price, Revenue and Gross Margin (2021-2026)
  35. 8.6.4 Grindeks Vigabatrin Product Portfolio
  36. 8.6.5 Grindeks Recent Developments
  37. 8.7 Endo International
  38. 8.7.1 Endo International Company Information
  39. 8.7.2 Endo International Business Overview
  40. 8.7.3 Endo International Vigabatrin Sales, Price, Revenue and Gross Margin (2021-2026)
  41. 8.7.4 Endo International Vigabatrin Product Portfolio
  42. 8.7.5 Endo International Recent Developments
  43. 8.8 Dr. Fisher Farma
  44. 8.8.1 Dr. Fisher Farma Company Information
  45. 8.8.2 Dr. Fisher Farma Business Overview
  46. 8.8.3 Dr. Fisher Farma Vigabatrin Sales, Price, Revenue and Gross Margin (2021-2026)
  47. 8.8.4 Dr. Fisher Farma Vigabatrin Product Portfolio
  48. 8.8.5 Dr. Fisher Farma Recent Developments
  49. 8.9 Cipla
  50. 8.9.1 Cipla Company Information
  51. 8.9.2 Cipla Business Overview
  52. 8.9.3 Cipla Vigabatrin Sales, Price, Revenue and Gross Margin (2021-2026)
  53. 8.9.4 Cipla Vigabatrin Product Portfolio
  54. 8.9.5 Cipla Recent Developments
  55. 8.10 Benta Pharma Industries
  56. 8.10.1 Benta Pharma Industries Company Information
  57. 8.10.2 Benta Pharma Industries Business Overview
  58. 8.10.3 Benta Pharma Industries Vigabatrin Sales, Price, Revenue and Gross Margin (2021-2026)
  59. 8.10.4 Benta Pharma Industries Vigabatrin Product Portfolio
  60. 8.10.5 Benta Pharma Industries Recent Developments
  61. 8.11 Amneal Pharma
  62. 8.11.1 Amneal Pharma Company Information
  63. 8.11.2 Amneal Pharma Business Overview
  64. 8.11.3 Amneal Pharma Vigabatrin Sales, Price, Revenue and Gross Margin (2021-2026)
  65. 8.11.4 Amneal Pharma Vigabatrin Product Portfolio
  66. 8.11.5 Amneal Pharma Recent Developments
9 Value Chain and Sales Channels Analysis
  1. 9.1 Vigabatrin Value Chain Analysis
  2. 9.1.1 Vigabatrin Key Raw Materials
  3. 9.1.2 Raw Materials Key Suppliers
  4. 9.1.3 Manufacturing Cost Structure
  5. 9.1.4 Vigabatrin Production Mode & Process
  6. 9.2 Vigabatrin Sales Channels Analysis
  7. 9.2.1 Direct Comparison with Distribution Share
  8. 9.2.2 Vigabatrin Distributors
  9. 9.2.3 Vigabatrin Customers
10 Concluding Insights
    11 Appendix
    1. 11.1 Reasons for Doing This Study
    2. 11.2 Research Methodology
    3. 11.3 Research Process
    4. 11.4 Authors List of This Report
    5. 11.5 Data Source
    6. 11.5.1 Secondary Sources
    7. 11.5.2 Primary Sources
    8. 11.6 Disclaimer

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $3,950USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research
    Talk to an analyst